UCM 707Potent anandamide transport inhibitor CAS# 390824-20-1 |
- Laminin (925-933)
Catalog No.:BCC1015
CAS No.:110590-60-8
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 390824-20-1 | SDF | Download SDF |
| PubChem ID | 10199993 | Appearance | Powder |
| Formula | C25H37NO2 | M.Wt | 383.57 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in ethanol and to 100 mM in DMSO | ||
| Chemical Name | (5Z,8Z,11Z,14Z)-N-(furan-3-ylmethyl)icosa-5,8,11,14-tetraenamide | ||
| SMILES | CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCC1=COC=C1 | ||
| Standard InChIKey | FZNNBSHTNRBBBD-DOFZRALJSA-N | ||
| Standard InChI | InChI=1S/C25H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-25(27)26-22-24-20-21-28-23-24/h6-7,9-10,12-13,15-16,20-21,23H,2-5,8,11,14,17-19,22H2,1H3,(H,26,27)/b7-6-,10-9-,13-12-,16-15- | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent endocannabinoid transport inhibitor. IC50 values are 0.8 and 30 μM for inhibition of the anandamide transporter and FAAH respectively. Ki values are 4700, 67 and > 5000 nM for CB1, CB2 and VR1 receptors respectively. Potentiates hypokinetic and antinociceptive effects of anandamide in vivo. |
UCM 707 Dilution Calculator
UCM 707 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6071 mL | 13.0354 mL | 26.0709 mL | 52.1417 mL | 65.1772 mL |
| 5 mM | 0.5214 mL | 2.6071 mL | 5.2142 mL | 10.4283 mL | 13.0354 mL |
| 10 mM | 0.2607 mL | 1.3035 mL | 2.6071 mL | 5.2142 mL | 6.5177 mL |
| 50 mM | 0.0521 mL | 0.2607 mL | 0.5214 mL | 1.0428 mL | 1.3035 mL |
| 100 mM | 0.0261 mL | 0.1304 mL | 0.2607 mL | 0.5214 mL | 0.6518 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ingenol 20-palmitate
Catalog No.:BCN7678
CAS No.:39071-33-5
- GS 39783
Catalog No.:BCC7233
CAS No.:39069-52-8
- Buxbodine D
Catalog No.:BCN5448
CAS No.:390362-53-5
- Buxbodine B
Catalog No.:BCN5447
CAS No.:390362-51-3
- 9-Methoxycamptothecine
Catalog No.:BCN1219
CAS No.:39026-92-1
- Guggulsterone E
Catalog No.:BCC8181
CAS No.:39025-24-6
- Z-Guggulsterone
Catalog No.:BCC7712
CAS No.:39025-23-5
- 3-Epiwilsonine
Catalog No.:BCN5446
CAS No.:39024-15-2
- Wilsonine
Catalog No.:BCN5445
CAS No.:39024-12-9
- (E)-2-(3-(3,4-dimethoxyphenyl)acryloyloxy)succinic acid
Catalog No.:BCN8545
CAS No.:39015-77-5
- Picroside II
Catalog No.:BCN6323
CAS No.:39012-20-9
- Epimedoside A
Catalog No.:BCN2886
CAS No.:39012-04-9
- Karakoline
Catalog No.:BCC8331
CAS No.:39089-30-0
- Ajmalan-17-one
Catalog No.:BCN3519
CAS No.:3911-19-1
- Nigranoic acid
Catalog No.:BCN2399
CAS No.:39111-07-4
- PD318088
Catalog No.:BCC2539
CAS No.:391210-00-7
- PD0325901
Catalog No.:BCC1277
CAS No.:391210-10-9
- N-Me-Ala-OH.HCl
Catalog No.:BCC2619
CAS No.:3913-67-5
- Trimebutine
Catalog No.:BCC4615
CAS No.:39133-31-8
- Ac-His-OH.H2O
Catalog No.:BCC2953
CAS No.:39145-52-3
- (E)-Cinnamyl-(Z)-p-coumarate
Catalog No.:BCN7694
CAS No.:391682-51-2
- Oxyresveratrol 2-O-beta-D-glucopyranoside
Catalog No.:BCN1448
CAS No.:392274-22-5
- Ginsenoside Compound K
Catalog No.:BCN1246
CAS No.:39262-14-1
- Sotalol
Catalog No.:BCC4356
CAS No.:3930-20-9
Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors.[Pubmed:12750028]
Eur J Med Chem. 2003 Apr;38(4):403-12.
In the present work we describe the synthesis and the in vitro evaluation of a series of arachidonic acid derivatives of general structure I as endocannabinoid transporter inhibitors. In addition, we report the first in vivo studies of the most potent derivative (4, UCM707) within this series. The majority of compounds studied are highly potent (IC(50)=24-0.8 micro M) and selective endocannabinoid uptake inhibitors with very low affinities for either the enzyme fatty acid amide hydrolase (IC(50)=30-113 micro M) or for cannabinoid receptor subtype 1 (CB(1)), cannabinoid receptor subtype 2 (CB(2)) and vanilloid receptor subtype 1 (VR(1)) (K(i)=1000-10000 nM). Among them, (5Z,8Z,11Z,14Z)-N-(fur-3-ylmethyl)icosa-5,8,11,14-tetraenamide (UCM707) behaves as the most potent endocannabinoid transporter inhibitor described to date (IC(50)=0.8 micro M) and exhibits improved potency for the anandamide transporter, high selectivity for CB(1) and VR(1) receptors, and modest selectivity for CB(2). In vivo it enhances the analgesia and hypokinetic effects induced by a subeffective dose of anandamide.
Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.[Pubmed:12672252]
J Med Chem. 2003 Apr 10;46(8):1512-22.
A new series of arachidonic acid derivatives were synthesized and evaluated as inhibitors of the endocannabinoid uptake. Most of them are able to inhibit anandamide uptake with IC(50) values in the low micromolar range (IC(50) = 0.8-24 microM). In general, the compounds had only weak effects upon CB(1), CB(2), and VR(1) receptors (K(i) > 1000-10000 nM). In addition, there was no obvious relationship between the abilities of the compounds to affect anandamide uptake and to inhibit anandamide metabolism by fatty acid amidohydrolase (FAAH; IC(50) = 30-113 microM). This indicates that the compounds do not exert their effects secondarily to FAAH inhibition. It is hoped that these compounds, particularly the most potent in this series (compound 5, UCM707, with IC(50) values for anandamide uptake and FAAH of 0.8 and 30 microM, respectively), will provide useful tools for the elucidation of the role of the anandamide transporter system in vivo.
